

Supplemental Figure: Patient enrollment flowchart. Two hundred two patients were screened for enrollment; 55 patients failed screening, resulting in 147 patients being enrolled (n = 72 in the rosuvastatin arm, n = 75 in the placebo arm). *High-sensitivity C-reactive protein level <2 mg/L. **CD8+ T-cell expression of CD38 and HLA-DR antigens <19%. †Patient found to have very high coronary calcium score by computed tomography on same day as screening, deemed unethical for patient to be potentially randomized to placebo. Abbreviations: CrCL, creatinine clearance; HIV-1, human immunodeficiency virus type 1; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; LFTs, liver function tests; TG, triglycerides. *Used with permission from Clinical Infectious Diseases (Oxford University Press, 2013)¹⁵.*

